Long-term effects, immune reactions, medicine interactions, route-specific risks, product impurities and the real composition or sterility of unapproved products remain uncertain
The most commonly reported side effects are mild and transient, including injection site reactions (redness, slight swelling, or tenderness), mild headaches during the initial days of use, and occasional dizziness or lightheadedness, particularly when starting the peptide
It has not been evaluated by the MHRA, the FDA, or any other regulatory authority for safety or efficacy in any application
There is no oral form of this blend that survives digestion, which is another reason the protocol is framed entirely around a small subcutaneous dose